We serve Chemical Name:pp1 CAS:172889-26-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:pp1
CAS.NO:172889-26-8
Synonyms:1-(tert-Butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;3-(4-Methylphenyl)-1-(2-methyl-2-propanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine;1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1,1-dimethylethyl)-3-(4-methylphenyl)-;4-Amino-5-(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine;1H-Pyrazolo[3,4-d]pyrimidin-4-amine (1-(1,1-dimethylethyl)-3-(4-methylphenyl);1-tert-butyl-3-(4-methylphenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine;pp1
Molecular Formula:C16H19N5
Molecular Weight:281.356
HS Code:2933990090
Physical and Chemical Properties:
Melting point:205-207ºC
Boiling point:478.8±40.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.652
PSA:69.62000
Exact Mass:281.164032
LogP:3.11
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2811 6.1 / PGIII
Packing Group:
Contact us for information like 1-(tert-Butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pp1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(tert-Butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Use and application,1-(tert-Butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine technical grade,usp/ep/jp grade.
Related News: As many as 9,000 medical workers in Hong Kong have pledged to strike this week, a threat that alarms the territory��s officials as they are struggling to contain the coronavirus outbreak. pp1 manufacturer As many as 9,000 medical workers in Hong Kong have pledged to strike this week, a threat that alarms the territory��s officials as they are struggling to contain the coronavirus outbreak. pp1 supplier As Reuters reported last month, Lilly tapped the Washington D.C. law firm Covington & Burling LLP to investigate the alleged alterations, which the employees said were meant to downplay serious quality control problems at the plant producing the drugmaker’s COVID-19 antibody treatment. pp1 vendor This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies. pp1 factory This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.
